Semaglutide vs Dulaglutide

Semaglutide generally achieves greater A1C reduction and weight loss than dulaglutide. The SUSTAIN and PIONEER trial programs demonstrated that semaglutide 1 mg weekly reduces A1C by approximately 1.5-1.8% from baseline, compared to approximately 1.1-1.5% for dulaglutide 1.5 mg weekly in the AWARD trials.

Weight loss is a notable differentiator: semaglutide 1 mg produces average weight loss of 4-6 kg, while dulaglutide 1.5 mg achieves approximately 2-3 kg. Higher doses of each drug (semaglutide 2 mg, dulaglutide 4.5 mg) produce greater effects.

Both drugs have demonstrated cardiovascular benefits. The SUSTAIN-6 trial showed semaglutide reduced major adverse cardiovascular events (MACE) by 26%. The REWIND trial showed dulaglutide reduced MACE by 12% in a broader, lower-risk population. Both are now indicated to reduce cardiovascular risk in patients with type 2 diabetes and established or at high risk for cardiovascular disease.

Both drugs share the common GLP-1 receptor agonist side effects: nausea, vomiting, diarrhea, constipation, and abdominal pain. These gastrointestinal effects are most pronounced during dose initiation and titration and typically improve over weeks.

Nausea rates are broadly similar between the two drugs, occurring in approximately 15-20% of patients. Semaglutide may cause slightly more gastrointestinal side effects at higher doses, though head-to-head data are limited.

Both drugs carry warnings about thyroid C-cell tumors (based on rodent studies), pancreatitis risk, and the potential for hypoglycemia when combined with insulin or sulfonylureas. Neither drug should be used in patients with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.

Injection site reactions are generally mild with both drugs. Dulaglutide uses a single-dose pen that does not require needle handling, which may reduce injection anxiety.

There is a significant cost difference between these drugs at list price. Both are expensive brand-name medications: semaglutide (Ozempic) lists at approximately $900-$1,000/month, and dulaglutide (Trulicity) at approximately $800-$900/month. Actual out-of-pocket costs depend heavily on insurance coverage and manufacturer copay programs.

Neither drug is currently available as a generic. Both manufacturers offer savings cards that can reduce copays to $25-$150/month for commercially insured patients. Medicare Part D coverage varies.

Semaglutide is also available as an oral tablet (Rybelsus), typically at a similar price point, providing an option for patients who prefer to avoid injections.

Both are administered once weekly by subcutaneous injection, which is a major convenience advantage over daily injectable or multiple daily oral medications.

Dulaglutide uses a ready-to-use single-dose pen with a hidden, pre-attached needle — the patient never sees or handles a needle. Semaglutide (Ozempic) uses a multi-dose pen that requires attaching a new needle for each injection and dialing the dose.

Dulaglutide's device may be easier for patients new to self-injection or those with needle anxiety. Semaglutide's multi-dose pen is smaller and requires refrigeration only before first use.

Semaglutide offers the unique option of oral administration (Rybelsus), though it must be taken on an empty stomach with minimal water, 30 minutes before food — which some patients find inconvenient.

Semaglutide may be preferred for patients who need maximum A1C reduction and weight loss, or those who prefer an oral option (Rybelsus). Its cardiovascular data (26% MACE reduction) is among the strongest in the GLP-1 class.

Dulaglutide may be preferred for patients who are new to injectable therapy (easier pen device), those who prioritize simplicity, or when insurance formulary placement favors it. Its cardiovascular benefit was demonstrated in a broader, more generalizable population (REWIND).

Both are excellent GLP-1 receptor agonists with proven cardiovascular benefits. Insurance coverage and formulary status often play a significant role in the choice. Discuss options with your healthcare provider and check your insurance coverage.